Newly diagnosed Diffuse Intrinsic Pointine Glioma (DIPG) or Medulloblastoma in relapse/progression in children research hub

Phase IB clinical trial to assess the safety, tolerability, and preliminary efficacy of AloCELYVIR (Mesenchymal allogenic cells + ICOVIR-5) in children, adolescent and young adults with newly diagnosed diffuse intrinsic pointine glioma (DIPG) in combination with radiotherapy or medulloblastoma in relapse/progression in monotherapy.

This study is testing a new treatment called AloCelyvir for children and young adults with two types of brain cancer: newly diagnosed DIPG or medulloblastoma that has returned. It's looking to see if the treatment is safe and what effects it might have.